Pulmonx Corp (LUNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmonx Corp (LUNG) has a cash flow conversion efficiency ratio of -0.221x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.10 Million) by net assets ($45.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Pulmonx Corp to measure how many days the company can operate on defensive assets alone.
Pulmonx Corp - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Pulmonx Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pulmonx Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmonx Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Green Cross Medical Science Corporation
KQ:142280
|
-0.003x |
|
SAMRYOONG Co.Ltd
KQ:014970
|
0.052x |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
0.006x |
|
Gapwaves AB Series B
ST:GAPW-B
|
-0.107x |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
-0.002x |
|
OPAL Fuels Inc
NASDAQ:OPAL
|
0.038x |
|
Unick Corporation
KQ:011320
|
0.105x |
|
Sachem Capital Corp
NYSE MKT:SACH
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Pulmonx Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pulmonx Corp from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Pulmonx Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $54.12 Million | $-32.45 Million | -0.600x | -63.14% |
| 2024-12-31 | $85.81 Million | $-31.54 Million | -0.368x | -15.62% |
| 2023-12-31 | $118.31 Million | $-37.61 Million | -0.318x | -8.46% |
| 2022-12-31 | $154.01 Million | $-45.14 Million | -0.293x | -36.70% |
| 2021-12-31 | $193.24 Million | $-41.43 Million | -0.214x | -58.27% |
| 2020-12-31 | $226.13 Million | $-30.63 Million | -0.135x | -222.24% |
| 2019-12-31 | $-187.38 Million | $-20.77 Million | 0.111x | +0.81% |
| 2018-12-31 | $-167.33 Million | $-18.39 Million | 0.110x | -99.85% |
| 2017-12-31 | $-63.18K | $-4.64 Million | 73.407x | +10136.98% |
| 2016-12-31 | $-2.84 Million | $-2.03 Million | 0.717x | -25.61% |
| 2015-12-31 | $-2.65 Million | $-2.56 Million | 0.964x | +1.67% |
| 2014-12-31 | $-1.41 Million | $-1.34 Million | 0.948x | +107.46% |
| 2013-12-31 | $-1.78 Million | $-811.78K | 0.457x | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more